Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quince Therapeutics ( (QNCX) ) has shared an update.
On May 18, 2026, Quince Therapeutics completed the stock-for-stock acquisition of clinical-stage Orphai Therapeutics, adding the LAM-001 inhaled rapamycin program and related orphan drug-designated indications to its portfolio, while also appointing former Orphai chief executive Brigette Roberts, M.D., to Quince’s board as a Class III director and as Chief Corporate Affairs Officer under largely unchanged compensation terms. The company simultaneously secured a private placement of up to $187 million through the issuance of Series C non-voting convertible preferred stock and warrants, adopted a new Series C preferred share structure with defined conversion limits and governance protections, and approved sizable retention bonuses for senior executives, moves that collectively reshape its capital structure, extend its funding runway toward late-decade Phase 2 readouts in multiple pulmonary indications, and strengthen management oversight during the integration of Orphai’s assets.
The most recent analyst rating on (QNCX) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sustained losses, and significant ongoing cash burn) and continued listing/valuation uncertainty. Technical indicators are mixed but generally soft, while the low P/E offers only limited valuation support given the development-stage profile.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Quince Therapeutics, Inc. is a Nasdaq-listed biotechnology company focused on developing disease-modifying therapies for rare and serious pulmonary conditions. Its pipeline now centers on LAM-001, a once-daily inhaled formulation of sirolimus (rapamycin), targeting pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and other fibrotic and vascular lung diseases.
Average Trading Volume: 5,773,280
Technical Sentiment Signal: Sell
Current Market Cap: $18.75M
For an in-depth examination of QNCX stock, go to TipRanks’ Overview page.